iBio's IBIO-610 plus semaglutide cut lean-mass share of NHP weight loss to 6% vs 22%

iBio, Inc.

In an 8-week obese NHP study (n=6 per group), fat was 93% of weight lost with single-dose IBIO-610 plus twice-weekly semaglutide, vs 77% with semaglutide alone.
Lean mass made up 6% of weight lost with IBIO-610 plus semaglutide, versus 22% with semaglutide alone.
IBIO-610 produced 97% reduction in active Activin E serum levels at week 8 after a single IV dose; NHP half-life was 33.2 days, potentially supporting twice-yearly human dosing.
Data presented in an oral session at the EASD Annual Meeting on Oct. 1, 2026; iBio plans to start first-in-human trials of IBIO-610 in the first half of 2027.
CEO/CSO Martin Brenner framed IBIO-610 as addressing the quality-of-weight-loss gap left by GLP-1 therapies; all results are preclinical.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.